These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study. Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788 [TBL] [Abstract][Full Text] [Related]
4. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Basiliximab Versus Daclizumab in Kidney Transplantation: A Meta-Analysis. Sun ZJ; Du X; Su LL; Zhang XD; Wang W Transplant Proc; 2015 Oct; 47(8):2439-45. PubMed ID: 26518947 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of induction therapy on acute rejection and graft outcomes in African American kidney transplantation. Hammond EB; Taber DJ; Weimert NA; Egidi MF; Bratton CF; Lin A; McGillicuddy JW; Chavin KD; Baliga PK Clin Transplant; 2010; 24(1):40-7. PubMed ID: 19236436 [TBL] [Abstract][Full Text] [Related]
9. Anti-interleukin-2 receptor antibodies for the prevention of rejection in liver transplant recipients: a systematic review and meta-analysis. Zhang Y; Jin W; Cai X Ann Med; 2017 Aug; 49(5):365-376. PubMed ID: 27813419 [TBL] [Abstract][Full Text] [Related]